Blood–brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The blood-brain barrier (BBB) limits the uptake of most drugs by brain, and the traditional approach to the BBB problem is the use of medicinal chemistry to increase drug lipid solubility, and increase lipid-mediated transport across the BBB. This review advocates a new model to CNS drug discovery of BBB-penetrating small molecules, whereby drug candidates are screened for carrier-mediated transport (CMT) across the BBB. AREAS COVERED: CMT systems are expressed by genes within the Solute Carrier (SLC) Transporter Gene Family, which now totals > 400 transporter genes. Emphasis is placed on reconciliation of the substrate transporter profile (STP) of BBB transport in vivo with the STP of the cloned SLC transporter in vitro. This reconciliation is crucial to the identification, from sometimes a large number of candidates, of the respective SLC transporter that is responsible for BBB transport in vivo for a given class of nutrients. EXPERT OPINION: Dual track screening of a small molecule library for drugs that have the dual properties of affinity for a neural cell drug receptor target, and affinity for a BBB CMT transporter target, can lead to a revolution in how small molecule drugs are identified in CNS drug discovery programs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“brain endothelial transport systems regulate molecular exchanges between blood-and-brain and brain-and-blood (2, 128, 460, 682, 692, 693).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [460]
In the citing paper
“The GLUT1 uniporter transports glucose, the key energy metabolite for the CNS, down the concentration gradient (128, 460).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [460]
In the citing paper
“Carrier-mediated transport (CMT) enables solutes such as carbohydrates, amino acids (AA), monocarboxylic acids, hormones, fatty acids, nucleotides, inorganic ions, amines, choline, and vitamins to cross the BBB via substrate-specific transporters (2, 128, 460, 682, 692, 693).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [460]
In the citing paper
“and sodium-dependent multivitamin transporter (SMVT) transports multivitamins from blood-to-brain (2, 128, 460, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [460]
In the citing paper
“choline transporter like protein type 1 (CTL1) transports choline bidirectionally across the BBB, and sodium-dependent multivitamin transporter (SMVT) transports multivitamins from blood-to-brain (2, 128, 460, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [460]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734 · cited 1×
“In another review of small molecule drugs, 12% were active in the CNS, but if affective disorders were excluded, then only 1% of all drugs were pharmacologically active in brain [3].”
BackgroundGhose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1999) · Journal of Combinatorial Chemistry · doi:10.1021/cc9800071 · Cited by 3,068 · cited 1×
“In a review of > 7000 small molecule drugs in the Comprehensive Medicinal Chemistry database, only 5% of all drugs are active in the CNS, and those drugs are active only in a small group of CNS diseases, including depression, schizophrenia, and insomnia [2].”
BackgroundThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Self-citationDrug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Self-citationCordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750 · cited 1×
“A model ABC transporter at the BBB is p-glycoprotein (Pgp) [10], also known as multi-drug resistance type 1, which is ABCB1.”
BackgroundBrain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection
Oldendorf, W. (1971) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1971.221.6.1629 · Cited by 1,683 · cited 7×
“The STP of the BBB hexose transporter was defined in vivo in the rat [19,25-27], and includes the following:”
BackgroundMethodInfluentialKanai, Y., Segawa, H., Miyamoto, K.-I., Uchino, H., Takeda, E., & Endou, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.23629 · Cited by 1,109 · cited 12×
“The SLC transporter responsible for BBB transport of the neutral amino acids is the leucine-preferring, or L-system, which is now known as the LNAA transporter type 1, or LAT1 [38], which corresponds to SLC7A5 (Table 1).”
BackgroundInfluentialQuantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
Brain metabolism: a perspective from the blood-brain barrier
Pardridge, W. M. (1983) · Physiological Reviews · doi:10.1152/physrev.1983.63.4.1481 · Cited by 741 · cited 1×
“Therefore, these acidic amino acid transporters mediate the active efflux of glutamate and aspartate from brain to blood [59].”
BackgroundSelf-citationIdentification of monocarboxylate transporter 8 as a specific thyroid hormone transporter
Friesema, E. C. H., Ganguly, S., Abdalla, A., Fox, J. E. M., Halestrap, A. P., & Visser, T. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300909200 · Cited by 725 · cited 10×
“MCT8, which shares amino acid identity with MCT1 [32], transports both T4 and T3 with comparable affinity [60].”
BackgroundInfluential
Research works printed but not linked: 7
- Cornford EM, 1992, Cancer Res, 52, 138
- Takasato Y, 1984, Am J Physiol, 247, H484
- Dwyer KJ, 1993, Endocrinology, 132, 558, 10.1210/endo.132.2.8093876 · doi:10.1210/endo.132.2.8093876 · Paper page
- Gerhart DZ, 1997, Am J Physiol, 273, E207
- Berne RM, 1983, Fed Proc, 42, 3136
- Mejia AA, 1991, J Nucl Med, 32, 699
- Inoue T, 1999, J Nucl Med, 40, 399
Cited by
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
“Besides, small lipophilic molecules, with a molecular weight (MW) < 400 Da forming < 8 hydrogen bonds, can cross the BBB [27].”
BackgroundEstablishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670
Elucidation of Exosome Migration Across the Blood–Brain Barrier Model In Vitro
Chen, C. C., Liu, L., Ma, F., Wong, C. W., Guo, X. E., Chacko, J. V., Farhoodi, H. P., Zhang, S. X., Zimak, J., Ségaliny, A., et al. (2016) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-016-0458-3 · Cited by 537
CSF, blood-brain barrier, and brain drug delivery
Pardridge, W. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1171315 · Cited by 508
Self-citation
Metadata
- Authors
- Pardridge, W. M.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Pardridge, William M
- ORCID
- Pardridge, William M
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2015-05-02
- Volume
- 19
- Issue
- 8
- Pages
- 1059-1072
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2046677279
- Cited by
- 159
- References
- 72
- Citations by year
- 2026: 8 · 2025: 20 · 2024: 17 · 2023: 11 · 2022: 18 · 2021: 15 · 2020: 17 · 2019: 9 · 2018: 14 · 2017: 11 · 2016: 16 · 2015: 3
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Therapeutic Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- blood-brain barrier, carrier-mediated transport, solute carrier transporters, CNS drug discovery, small molecule drug candidates, transporter affinity, drug penetration into brain
- MeSH terms
- Animals, Biological Transport, Blood-Brain Barrier, Brain, Pharmaceutical Preparations, Humans, Lipids, Solubility, Drug Delivery Systems, Membrane Transport Proteins, Small Molecule Libraries, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood–brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. https://app.cochat.ai/papers/10.1517/14728222.2015.1042364
- The paper
- Pardridge, W. M. (2015). Blood–brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2015.1042364
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.